Targeted Hepatitis B Birth Vaccination May Increase Neonatal Infections

The Clinical Stakes of Neonatal Hepatitis B Prevention

Chronic hepatitis B virus infection remains a significant global health challenge, contributing to a substantial portion of the nearly 10 million annual cancer deaths worldwide, particularly through the development of hepatocellular carcinoma [1, 2]. Vertical transmission from mother to child is a primary driver of the chronic disease burden, as infants infected at birth face a high risk of becoming lifelong carriers [3, 4]. Clinical evidence has long established that the administration of the hepatitis B vaccine and immunoglobulin to newborns is highly effective at preventing neonatal infection [5, 6]. While universal birth-dose vaccination has served as a safety net for infants of unscreened or falsely negative mothers, recent policy shifts have moved toward targeted strategies based on maternal surface antigen status. A new study now evaluates the potential clinical consequences of this transition in the United States, raising critical questions about whether removing the universal mandate might inadvertently increase neonatal infections in everyday practice.

Modeling the Shift from Universal to Targeted Vaccination

In December 2025, the Advisory Committee on Immunization Practices voted to replace the universal hepatitis B birth-dose recommendation with shared clinical decision-making for infants born to mothers who screen negative for hepatitis B surface antigen. While the proposal does not alter recommendations for infants of unscreened mothers, it introduces a significant shift in clinical practice for the majority of neonatal cases. Under this targeted recommendation, the birth dose is specifically recommended for infants of screened-positive or unscreened mothers, whereas shared decision-making is recommended for infants of screened-negative mothers. To quantify how this transition might influence infection rates across the United States, researchers conducted a simulated study from September through November 2025. They utilized a compartmental model (a mathematical framework that simulates how individuals move between different health states, such as susceptible, infected, or immune) to analyze a US birth cohort of 3,659,289 infants. The simulation compared two distinct vaccine recommendations: universal birth-dose vaccination and targeted birth-dose vaccination. By comparing these strategies, the researchers sought to estimate the resulting numbers of neonatal and subsequent chronic hepatitis B virus infections. To account for statistical variability and ensure the robustness of the findings, uncertainty was incorporated into the model across 5000 iterations. This iterative process allowed the authors to generate a median estimate and a 95 percent percentile interval for potential infections. The analysis focused heavily on how birth-dose vaccination coverage among infants of unscreened mothers might fluctuate following the removal of a universal mandate. Historical data suggest that targeted recommendations often lead to unintended declines in vaccination rates, even among high-risk groups for whom the vaccine remains clinically indicated. For pediatricians and obstetricians, understanding these modeled outcomes is crucial for anticipating potential gaps in neonatal protection.

Projected Increases in Neonatal and Chronic Infections

The researchers focused on two primary outcomes to evaluate the impact of the policy shift: the total number of neonatal hepatitis B virus infections and the subsequent development of chronic cases. Under the current clinical landscape, which maintains a maternal screening rate of 86 percent, the universal birth-dose recommendation results in a median of 1292 neonatal infections (95 percent percentile interval [PI], 670 to 2228). This baseline serves as the benchmark for evaluating the potential epidemiological shifts associated with the transition to a targeted vaccination strategy. The simulation indicates that replacing the universal mandate with a targeted recommendation could significantly increase the disease burden. If vaccination coverage among infants born to unscreened mothers falls to 10 percent, the targeted approach is associated with 628 additional neonatal infections (95 percent PI, 340 to 1034). This 10 percent coverage rate is not a hypothetical minimum; rather, it mirrors historic coverage declines observed in clinical settings when universal recommendations are removed in favor of targeted strategies. Even under more optimistic scenarios where vaccination coverage among infants of unscreened mothers remains at 80 percent, the targeted strategy is associated with 69 additional infections (95 percent PI, -32 to 190). This 80 percent coverage rate mirrors levels typically seen under a universal recommendation, suggesting that the administrative and clinical simplicity of a universal birth-dose policy provides a safety net that targeted strategies struggle to replicate. For practicing physicians, these data highlight that any move away from universal vaccination may lead to an uptick in both acute neonatal and long-term chronic hepatitis B virus infections unless maternal screening rates are substantially improved to capture those currently missed by the healthcare system.

The High Threshold for Offsetting Clinical Risk

The logistical burden required to mitigate the risks of a targeted vaccination strategy is substantial, requiring a massive expansion of current maternal screening efforts. According to the findings, the number of additional pregnant individuals who would need to be screened to prevent excess infections depends heavily on the vaccination rates achieved among infants of unscreened mothers. If birth-dose coverage among these unscreened infants remains at 80 percent, clinicians and public health systems would still need to screen more than 100,000 additional pregnant individuals to offset the projected increase in neonatal hepatitis B virus infections. This requirement highlights the difficulty of maintaining current infection lows when the universal safety net is removed, even under highly optimistic vaccination scenarios. The clinical challenge becomes even more acute if vaccination coverage among infants of unscreened mothers follows historical trends and drops to 10 percent. In this scenario, the researchers calculated that more than 400,000 additional pregnant individuals would need to be screened to successfully offset the excess neonatal infections associated with a targeted recommendation. These findings indicate that a transition to targeted birth-dose recommendations will likely increase neonatal infections unless maternal screening rises substantially or vaccination coverage among unscreened infants exceeds current levels. Because historical data suggest such improvements in screening and targeted coverage are unlikely to occur spontaneously, the study authors emphasize that universal birth-dose vaccination remains a necessary safeguard against persistent gaps in maternal screening and the inherent complexities of shared clinical decision-making.

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer Journal for Clinicians. 2024. doi:10.3322/caac.21834

2. Jemal A, Bray F, Ferlay J, Ward E, Forman D. Global cancer statistics. CA A Cancer Journal for Clinicians. 2011. doi:10.3322/caac.20107

3. Sarin SK, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology International. 2015. doi:10.1007/s12072-015-9675-4

4. Deng M, Zhou X, Gao S, et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virology Journal. 2012. doi:10.1186/1743-422X-9-185

5. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006. doi:10.1136/bmj.38719.435833.7c

6. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis.. BMJ (Clinical research ed.). 2006. doi:10.1136/bmj.38719.435833.7C